Health Economics›Angiosarcoma›All lines of therapy

All lines of therapy

Angiosarcoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	~6.7 mo	~19.6 mo	~10	~R 572 464 PFS proxy · indirect	10
Pazopanib monotherapy Variant #01	—	R 22 754	28d	~4.3 mo	—	~5	~R 113 768 PFS proxy · indirect	1
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	~4.8 mo	~12.0 mo	~6	~R 13 317 PFS proxy · indirect	85

3 of 3 regimens shown